Publikationen, an denen er mitarbeitet CARLOS CAMPS HERRERO (48)

2024

  1. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

    Cell Communication and Signaling, Vol. 22, Núm. 1

  2. Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 1, pp. 190-215

2023

  1. A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

    Annals of Surgical Oncology, Vol. 30, Núm. 2, pp. 1225-1235

  2. ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients

    Annals of surgical oncology, Vol. 30, Núm. 2, pp. 1238-1239

  3. Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  4. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer

    Critical Reviews in Oncology/Hematology, Vol. 182

2022

  1. Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 13

  2. Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer

    Cancers, Vol. 14, Núm. 2

2021

  1. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study

    Materials Science and Engineering C, Vol. 122

  2. Analysis of the gut microbiota: An emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 11

  3. Characterization of circulating t cell receptor repertoire provides information about clinical outcome after pd-1 blockade in advanced non-small cell lung cancer patients

    Cancers, Vol. 13, Núm. 12

  4. Exosomal microRNAs in non-small cell lung cancer

    Translational Cancer Research, Vol. 10, Núm. 6, pp. 3128-3139

  5. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2363-2376

  6. Update on systemic treatment in early triple negative breast cancer

    Therapeutic Advances in Medical Oncology, Vol. 13

  7. dPCR application in liquid biopsies: divide and conquer

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 1, pp. 3-15

2020

  1. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer

    Expert Review of Molecular Diagnostics, Vol. 20, Núm. 6, pp. 575-582

  2. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

    Translational Lung Cancer Research, Vol. 9, Núm. 4, pp. 1074-1083

  3. Long term control stereotactic body radiotherapy (SBRT) for oligometastatic colorectal cancer: A single center study

    Chinese Clinical Oncology, Vol. 9, Núm. 2

  4. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort

    Modern Pathology, Vol. 33, Núm. 5, pp. 792-801

2019

  1. Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, pp. ii9